Elon Musk’s brain chip company, Neuralink, has announced that it has received approval from the US Food and Drug Administration (FDA) to commence studies involving humans.
Neuralink shared the news via a tweet, stating that the FDA approval allows them “to launch our first-in-human clinical study,” reports Sky News.
The company views this as a significant initial step towards utilizing their technology to assist numerous individuals in the future.
Although Neuralink did not provide specific details about the study’s objectives or the start date of the trials, they clarified that they are not currently recruiting participants.
Elon Musk, who previously stated that the devices are safe enough for his own children to use as test subjects, envisions their potential to address various conditions such as obesity, autism, depression, and schizophrenia.
Additionally, Musk believes that the technology could facilitate web browsing and even enable telepathic communication, reports Sky News.
While Mr. Musk has mentioned on multiple occasions since 2019 that Neuralink would begin human trials, the company only applied for FDA approval in early 2022.
The initial application was rejected due to concerns regarding the implant’s lithium battery, potential migration of its wires within the brain, and the safe removal of the device without causing damage to brain tissue.
The FDA emphasized the need to address these concerns before granting approval for human trials.
Established in 2016, Neuralink has been the subject of several federal investigations.
Recently, Swiss researchers demonstrated the technology’s potential by enabling a paralyzed individual from the Netherlands to walk simply by using his thoughts.
The system employed implants that wirelessly transmitted his thoughts to his legs and feet, reports Sky News.
Tell us your thoughts in the Facebook post and share this with your friends.